A cost-effectiveness modelling study of strategies to reduce risk of infection following primary hip replacement based on a systematic review

Nicholas Graves,1* Catherine Wloch,2 Jennie Wilson,3 Adrian Barnett,1 Alex Sutton,4 Nicola Cooper,4 Katharina Merollini,1 Victoria McCreanor,1 Qinglu Cheng,1 Edward Burn,1 Theresa Lamagni2 and Andre Charlett2

1School of Public Health and Social Work, Queensland University of Technology, Brisbane, QLD, Australia
2Public Health England, Colindale, UK
3College of Nursing, Midwifery and Healthcare, University of West London, London, UK
4Department of Health Sciences, University of Leicester, Leicester, UK

*Corresponding author

Declared competing interests of authors: none

Published July 2016
DOI: 10.3310/hta20540

Scientific summary

Reducing infection risk following primary hip replacement
Health Technology Assessment 2016; Vol. 20: No. 54
DOI: 10.3310/hta20540

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Total hip arthroplasty (THA) is common in the UK, and demand is rising as the population ages. There are risks with THA, and deep infection of the surgical site is reported in 0.7% of all cases. This uses up scarce health-care resources and impacts on the patients’ quality of life. Deep infections often lead to revision surgery, which is invasive, painful and costly. A range of strategies is employed in NHS hospitals to reduce the risk of deep infection following THA. However, no economic analysis has been undertaken to compare the value for money of competing prevention strategies. This information will enable policy-makers to identify a cost-effective approach to managing the risks of infection among patients who have a primary THA in NHS hospitals.

Objectives

To compare the costs and health benefits of strategies to reduce the risk of deep infection following THA in NHS hospitals. To make recommendations to decision-makers about the cost-effectiveness of the alternatives.

Methods

An evidence synthesis exercise was completed and an economic decision-analytic model used to assess the cost-effectiveness of nine different treatment strategies to reduce the risk of surgical site infection (SSI) following THA carried out in NHS hospitals. Only deep infections were included. Superficial infections were excluded because they are relatively easy to treat and are not associated with severe or long-term effects for the patient.

Data sources and extraction

Literature searches using MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature and the Cochrane Central Register of Controlled Trials, were undertaken to identify infection prevention strategies in the period 1966–2012. Relevant journals, conference proceedings and bibliographies of retrieved papers were hand-searched. Orthopaedic surgeons and infection prevention experts were also consulted. The search was limited to English-language papers. The selection of evidence was conducted by two independent reviewers and discrepancies were resolved. The patient, intervention, comparison and outcome framework revealed the population consisted of patients undergoing total hip replacement (THR); the intervention was infection control strategies to prevent THR-related SSI; the comparison was infection control strategies compared with other control strategies in the mixed-treatment comparison network; and the outcome was the number of THR-related SSIs. Studies were included if they were interventions that reported THA-related deep SSI as an outcome. Antibiotic prophylaxis, antibiotic-impregnated cement and ventilation systems used in the operating theatre were indicated. The key outcome variables evaluated were total number of THRs performed and the total number of deep SSIs diagnosed following the THR procedures.

Data synthesis

A mixed-treatment comparison was used to synthesise evidence of effectiveness of nine different treatment strategies, treatments (Ts) 1–9. The statistical method allowed estimates of the relative effectiveness of each treatment in a network to be compared. Judgements based on existing evidence were made regarding the size of the treatment effect. T1 was the reference for comparison and included no antibiotic prophylaxis, plain cement and conventional ventilation without laminar airflow system. This was trialled against eight other treatments.
Economic modelling
We used a Markov model with health states to describe the treatment paths a patient could follow if they developed a deep SSI after THA. These were debridement, antibiotics and implant retention, a one-stage revision, the two stages of a two-stage revision and permanent resection. Also included were states for no infection, deep infection and successful treatment. All states in the model were mutually exclusive and had ‘cost’ and ‘quality-of-life’ tariffs attributed to them. The probability of patients transitioning between states over time was assigned. Costs and quality-adjusted life-years (QALYs) for each cycle were calculated for each competing treatment strategy. The model was run for 5 years until all patients had transitioned through the model. Total cost and QALYs across all cycles were summed for each treatment. Data to inform model parameters were taken from relevant NHS databases that were linked together. It would not be possible to run a prospective clinical trial to address the same research question.

Results
Twelve studies, of which six were randomised controlled trials and six were observational studies, involving 123,788 THRs and nine infection control strategies, were identified. The quality of the evidence was judged against four categories developed by the National Institute for Health and Care Excellence’s Methods for Development of NICE Public Health Guidance (http://publications.nice.org.uk/methods-for-the-development-of-nice-public-health-guidance-third-edition-pmg4). All evidence was found to fit the two highest categories of 1 and 2.

A cohort of 77,321 patients who had a primary THR in 2012 was simulated for conditions relevant to T1 (no systemic antibiotics, plain cement and conventional ventilation). All other treatment strategies reduced risk and resulted in fewer cases of deep infection with T6 (systemic antibiotics, antibiotic-impregnated cement and conventional ventilation) the most effective. T6 prevented a further 1481 cases of deep infection and led to the largest annual cost savings of £8,325,277 (95% uncertainty interval £17,981,040 to £5,765,832). The mean gains to health benefits measured by QALYs were greatest at 147 QALYs gained (95% uncertainty interval 585 to 1157 QALYs gained). Based on this analysis, T6 is the optimal decision, with the highest probability of being cost-effective, at 32%. Other treatments that include laminar airflow (T7) and the additional use of body exhaust suit (T9) are common among NHS trusts, yet lead to both high costs and lower health outcomes (£5,053,528 higher costs and 23 fewer QALYS for T7 vs. T6; and £9,106,352 higher costs and 84 fewer QALYS for T9 vs. T6).

Conclusions
The modelling results indicate that the combination of systemic antibiotics, antibiotic-impregnated cement and conventional operating theatre ventilation (T6) is the most effective strategy for reducing the risk of SSI following THA. It was associated with the greatest prevention of cases of SSI, the largest cost saving and gains to QALYs. Other strategies that are commonly used among NHS hospitals lead to higher cost and worse QALY outcomes. There are opportunities to save resources and improve health outcomes.

Funding
Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research and the Queensland Health Quality Improvement and Enhancement Programme (grant number 2008001769).
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 08/13/02. The contractual start date was in November 2009. The draft report began editorial review in August 2015 and was accepted for publication in January 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Graves et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk